Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy

NCT05222971 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

62

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Cancer
DNA Damage Repair Deficiency

Interventions

DRUG: Durvalumab
DRUG: Olaparib

Sponsor

Asan Medical Center